111 Inc - ADR

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

111 Inc achieves operational profitability in Q1 2024 earnings call

111 Inc's Q1 2024 performance reflects a shift towards profitability, driven by operational efficiency and strategic initiatives. While facing challenges in expense optimization, the company is well-positioned to capitalize on market opportunities through listing options and expansion plans.

111 Inc reports operational profitability and strategic growth initiatives in Q2 2024

111 Inc's Q2 2024 earnings call showcased operational profitability, cost reductions, and strategic advancements in digital transformation and supply chain management. The company's focus on growth in the health care industry, expansion of patents, and plans for further logistics network development position it for continued success amidst challenges and evolving market trends.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

111, Inc. (YI) CEO Junling Liu on Q1 2020 Results - Earnings Call Transcript

SHANGHAI, May 21, 2020 /PRNewswire/ --111, Inc. ("111" or the "Company") (NASDAQ: YI), a Company dedicated to digitally connecting patients with drugs and healthcare services in China, today announced its unaudited financial results for the first quarter ended March 31, 2020. First...

111, Inc. Announces First Quarter 2020 Unaudited Financial Results

111, Inc. (YI) CEO Junling Liu on Q4 2019 Results - Earnings Call Transcript

111, Inc.'s (YI) CEO Junling Liu on Q3 2019 Results - Earnings Call Transcript

Hovnanian Enterprises

Lexicon Pharmaceuticals

Contango Oil & Gas

We highlight five small-cap ETFs and stocks that have outperformed in September. These could be excellent plays for investors should the same trends prevail.

Small Caps Win in September: 5 Best ETFs & Stocks

111, Inc. (YI) CEO Junling Liu on Q2 2019 Results - Earnings Call Transcript

111, Inc's (YI) CEO Junling Liu on Q1 2019 Results - Earnings Call Transcript

News for 111 Inc - ADR Stock (YI)